paclitaxel

P4, N=22, Recruiting, University of Michigan Rogel Cancer Center | Trial completion date: Dec 2025 --> Jun 2026 | Trial primary completion date: Dec 2025 --> Jun 2026

Collectively, these results highlight nanoencapsulation as a promising strategy to potentiate PTX activity while improving safety for local breast cancer therapy. The distinct molecular responses of lipid and hybrid systems demonstrate that nanocarrier composition and structure modulate biological outcomes, underscoring the importance of rational nanocarrier design to overcome current therapeutic challenges.

Prompt cessation of paclitaxel and initiation of heart failure therapy led to clinical improvement. This case highlights the need for vigilance for cardiac toxicities in chemotherapy patients with cardio-oncology collaboration.

This integrated analysis establishes C. elegans as a tractable in vivo platform for dissecting both proliferative and meiotic consequences of paclitaxel. By linking spindle disruption, delayed DNA repair, and apoptosis with transcriptional reprogramming, the study provides mechanistic insight into germline vulnerability, reproductive side effects, and potential adaptive responses relevant to chemotherapy.

Management is predominantly based on adequate surgery and chemotherapy with carboplatin and paclitaxel, with the addition of anti-angiogenic therapy as indicated. Other molecular characteristics are important in distinct types of EOC, but the use of matched targeted therapies remains under investigation, as does the role of immunotherapy for EOC, for which trial data have been disappointing to date. Translationally enriched clinical trials will be important to further explore and validate accurate biomarkers to better guide clinical care.

To overcome these obstacles, we developed a composite biomimetic nanodelivery system comprising two distinct formulations: platelet membrane-coated liposomes encapsulating berberine (BBR) and ginsenoside Rg3 (RG3) (B@R/PL) for stromal modulation, and liposomes modified with a neutrophil extracellular trap (NET)-derived DNA-protein network co-loading paclitaxel (PTX) and a photothermal agent (PCP) (P&P/NL) for synergistic killing...Furthermore, the treatment reshaped the immune microenvironment, evidenced by markedly elevated levels of tumor necrosis factor-α (TNF-α), interferon-γ (IFN-γ), and interleukin-6 (IL-6), alongside decreased interleukin-10 (IL-10) in tumor tissues. Collectively, this TME-programming biomimetic strategy provides a promising approach with clinical translation potential to overcome TME barriers and achieve efficient anti-tumor and anti-metastasis therapy.

P2, N=90, Active, not recruiting, Akeso | Not yet recruiting --> Active, not recruiting | N=30 --> 90 | Trial completion date: Jan 2025 --> Dec 2026 | Trial primary completion date: Aug 2023 --> Aug 2025

ENETs are rare, aggressive tumors often diagnosed at an advanced stage. Combined adjuvant chemotherapy and radiotherapy were associated with improved outcomes. Molecular profiling may identify potential therapeutic targets.

P1, N=94, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2026 --> Mar 2027

P1/2, N=210, Recruiting, Merck Sharp & Dohme LLC | Trial primary completion date: Dec 2026 --> May 2028

P1, N=40, Active, not recruiting, City of Hope Medical Center | Trial completion date: Feb 2026 --> Jan 2027 | Trial primary completion date: Feb 2026 --> Jan 2027